journal
MENU ▼
Read by QxMD icon Read
search

Annals of Hematology

journal
https://www.readbyqxmd.com/read/28435987/rethinking-the-usefulness-of-bone-marrow-biopsy-on-treatment-decision-in-cll-patients-at-diagnosis
#1
Rafet Eren, Mehmet Hilmi Doğu, Servet Emir, Gülben Erdem Huq, Oğuzhan Okçu, Şermin Altındal, Osman Yokuş, Elif Suyanı
We aimed to investigate the role of bone marrow infiltration pattern (BMIP) and bone marrow reticulin fibrosis (BMRF) in determining treatment demand in patients with diagnosis of chronic lymphocytic leukemia (CLL). We retrospectively evaluated the data of 65 patients, who were followed with the diagnosis of CLL at Istanbul Training and Research Hospital, Department of Hematology, between July 2007 and June 2016. The median age of the patients was 64 years (range, 32-83). Twenty-three (35.4%) patients were female, and 42 (64...
April 24, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28434018/low-dose-nivolumab-induced-remission-in-refractory-classical-hodgkin-lymphoma
#2
LETTER
Yu-Yan Hwang, Pek-Lan Khong, Yok-Lam Kwong
No abstract text is available yet for this article.
April 22, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28432411/donor-lymphocyte-infusion-reversed-graft-rejection-in-matched-unrelated-donor-hematopoietic-stem-cell-transplantation-for-a-child-with-thalassemia
#3
LETTER
Anthony P Y Liu, Janette S Y Kwok, Alan K S Chiang, Godfrey C F Chan, Pamela P W Lee, S Y Ha, Daniel K L Cheuk
No abstract text is available yet for this article.
April 22, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28432410/complete-radiologic-and-molecular-response-of-hiv-negative-primary-effusion-lymphoma-with-short-course-lenalidomide
#4
LETTER
Thomas S Y Chan, Vivien Mak, Yok-Lam Kwong
No abstract text is available yet for this article.
April 22, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28424883/acute-basophilic-leukemia-with-add-3-q12-accompanied-by-histamine-excess-symptoms
#5
LETTER
Junji Koya, Toshio Ibaraki, Ieharu Yamazaki, Fumihiko Nakamura, Mineo Kurokawa
No abstract text is available yet for this article.
April 19, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28421266/reactive-oxygen-species-mediated-t-lymphocyte-abnormalities-in-an-iron-overloaded-mouse-model-and-iron-overloaded-patients-with-myelodysplastic-syndromes
#6
Jie Chen, Wen-Yi Lu, Ming-Feng Zhao, Xiao-Li Cao, Yan-Yu Jiang, Xin Jin, Ping Xu, Ting-Ting Yuan, Yu-Chen Zhang, Xiao Chai, Juan-Xia Meng, Qing Li, Xia Xiao, Juan Mu, De-Guan Li, Ai-Ping Qi
The adverse effects of iron overload have raised more concerns as a growing number of studies reported its association with immune disorders. This study aimed to investigate alterations in the immune system by iron overload in patients with myelodysplastic syndrome (MDS) and an iron-overloaded mouse model. The peripheral blood from patients was harvested to test the effect of iron overload on the subsets of T lymphocytes, and the level of reactive oxygen species (ROS) was also evaluated. The data showed that iron-overloaded patients had a lower percentage of CD3(+) T cells and disrupted T cell subsets, concomitant with higher ROS level in lymphocytes...
April 18, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28417157/impact-of-cachexia-on-outcomes-in-aggressive-lymphomas
#7
Reem Karmali, Taha Alrifai, Ibtihaj A M Fughhi, Ronald Ng, Vineela Chukkapalli, Palmi Shah, Sanjib Basu, Sunita Nathan, Kelly Szymanski-Grant, Leo I Gordon, Parameswaran Venugopal, Frank J Penedo, Jeffrey A Borgia
Cancer cachexia is defined as a state of involuntary weight loss, attributed to altered body composition with muscle mass loss and/or loss of adiposity. Identifying the association between cancer cachexia and outcomes may pave the way for novel agents that target the cancer cachexia process. Clinical parameters for measurement of cancer cachexia are needed. We conducted a single-institution retrospective analysis that included 86 NHL patients with the aim of identifying an association between cancer cachexia and outcomes in aggressive lymphomas using the cachexia index (CXI) suggested by Jafri et al...
April 17, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28409228/diagnosis-and-treatment-of-multiple-myeloma-in-germany-analysis-of-a-nationwide-multi-institutional-survey
#8
Maximilian Merz, Lenka Kellermann, Wolfram Poenisch, Hans-Joachim Tischler, Joern Kohnke, Wolfgang Knauf, Hartmut Goldschmidt
A nationwide, multi-institutional survey was performed in 2011 and 2015 to analyze routine practice for myeloma patients outside clinical trials in Germany. We contacted university hospitals, community hospitals, and office-based hematologists in order to enter clinical data from newly diagnosed and relapsed patients into an online platform. Complete datasets were available for 478 (2011) and 515 (2015) patients. While median age at diagnosis increased from 70 to 72 years, patients had fewer concomitant diseases (2011 61%; 2015 51%) and presented with equal performance status (ECOG 0-1, 2011 66%; 2015 68%)...
April 13, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28396947/assessing-baseline-bone-marrow-status-in-advanced-stage-hodgkin-lymphoma-does-it-have-any-purpose
#9
LETTER
Hugo J A Adams, Thomas C Kwee
No abstract text is available yet for this article.
April 11, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28391438/purpuric-exanthema-in-a-patient-with-hairy-cell-leukemia-treated-with-cladribine-and-allopurinol
#10
LETTER
Pablo Espinosa Lara, Virginia Quirós Redondo, Marta Aguado Lobo, José Jiménez-Reyes
No abstract text is available yet for this article.
April 8, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28389687/advances-in-the-treatment-of-relapsed-refractory-chronic-lymphocytic-leukemia
#11
REVIEW
C Shustik, I Bence-Bruckler, R Delage, C J Owen, C L Toze, S Coutre
Treatment of chronic lymphocytic leukemia (CLL) has advanced with the introduction of chemoimmunotherapy (CIT) agents that have improved the outcomes of frontline therapy. However, most treated patients will relapse and require subsequent therapy. This review focuses on recent advances in the treatment of relapsed or refractory CLL. Until recently, treatment options for relapsed CLL were of limited efficacy. Retreatment with fludarabine, cyclophosphamide, and rituximab (FCR) was recommended for patients with a durable response to first-line FCR, although acquired genetic aberrations, impaired marrow reserve, and comorbidities often made this suboptimal therapy for many patients...
April 7, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28378040/interferon-free-antiviral-treatment-of-chronic-hepatitis-c-in-patients-affected-by-%C3%AE-thalassemia-major
#12
LETTER
Elisa Biliotti, Donatella Palazzo, Marco Serani, Alessandro M Silvestri, Lorenzo Volpicelli, Rozenn Esvan, Cristiana Franchi, Martina Spaziante, Francesco Sorrentino, Gloria Taliani
No abstract text is available yet for this article.
April 5, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28378039/idiopathic-hypereosinophilic-syndrome-manifesting-with-eosinophilic-cholecystitis-and-recurrent-gastroenteritis
#13
LETTER
Yutaka Shimazu, Hiromitsu Nagata
No abstract text is available yet for this article.
April 4, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28374164/bilateral-sciatic-nerve-neurolymphomatosis-pet-ct-findings
#14
LETTER
Luis Gorospe, José Ignacio Gallego-Rivera, María Eugenia Rioja-Martín, Anabelle Chinea-Rodríguez
No abstract text is available yet for this article.
April 3, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28374163/carboplatin-instead-of-cisplatin-in-combination-with-dexamethasone-high-dose-cytarabine-with-or-without-rituximab-dhac-r-is-an-effective-treatment-with-low-toxicity-in-hodgkin-s-and-non-hodgkin-s-lymphomas
#15
B Tessoulin, P Thomare, E Delande, J Moynard, T Gastinne, A Moreau, C Bossard, B Mahé, N Blin, V Dubruille, C Touzeau, J S Boudreault, F Perrin, A Lok, T Guillaume, A Garnier, P Peterlin, P Gallas, P Chevallier, P Moreau, Steven Le Gouill
The DHAP regimen (high-dose cytarabine in combination with dexamethasone and cisplatin) with or without rituximab (DHAP+/-R) is one of the most common regimens in daily practice. It is considered the standard treatment for relapse or refractory Hodgkin's and non-Hodgkin's lymphoma (NHL). Cisplatin nephrotoxicity is a major concern, and other platinum compounds are being tried. We performed a monocentric retrospective analysis to evaluate the use of carboplatin, so-called DHAC+/-R regimen. The purpose was to assess the toxicity of the DHAC+/-R regimen in real-life...
April 3, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28374162/peripheral-blood-cytogenetics-allows-treatment-monitoring-and-early-identification-of-treatment-failure-to-lenalidomide-in-mds-patients-results-of-the-le-mon-5-trial
#16
Friederike Braulke, Xenia Schulz, Ulrich Germing, Esther Schuler, Uwe Platzbecker, Florian Nolte, Wolf-Karsten Hofmann, Aristoteles Giagounidis, Katharina Götze, Michael Lübbert, Richard F Schlenk, Julie Schanz, Ulrike Bacher, Arnold Ganser, Guntram Büsche, Anne Letsch, Philippe Schafhausen, Gesine Bug, Tim H Brümmendorf, Rainer Haas, Lorenz Trümper, Katayoon Shirneshan, Detlef Haase
Transfusion-dependent patients with low- or intermediate-1-risk myelodysplastic syndrome, <5% bone marrow (BM) blasts and isolated 5q-deletion received lenalidomide within the German MDS study group phase-II clinical trial LE-MON-5 (EudraCT:2008-001866-10) of the University of Duesseldorf, Germany. Cytogenetic monitoring was performed by chromosome banding analyses (CBA) of BM cells and fluorescence in situ hybridization (FISH) analyses of peripheral blood (PB) mononuclear CD34+ cells using extended probe panels...
April 3, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28361297/neuropathic-pain-in-patients-with-sickle-cell-disease-a-cross-sectional-study-assessing-teens-and-young-adults
#17
Fabricio Dias Antunes, Vynicius Goltran Sobral Propheta, Hulemar Andrade Vasconcelos, Rosana Cipolotti
Chronic pain conditions are little studied and may be underestimated in sickle cell disease (SCD). The aim of this study was to identify the occurrence and characteristics of neuropathic pain (NP) in SCD patients. A sample of 56 patients was chosen from a total of 554 patients submitted to the inclusion criteria between 2015 and 2016. The Leeds assessment of neuropathic symptoms and signs scale was used for detecting NP. The groups with and without NP were compared by sex, age, use of hydroxyurea, and sensory changes through Chi-square, Fisher's exact, ANOVA, and Kruskal-Wallis tests...
March 30, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28361296/women-with-homozygous-at-deficiency-type-ii-heparin-binding-site-hbs-are-at-high-risk-of-pregnancy-loss-and-pregnancy-complications
#18
Julia Kraft, Raute Sunder-Plassmann, Christine Mannhalter, Peter Quehenberger, Gernot Tews, Martin Langer, Ingrid Pabinger
Data regarding outcome and therapy of pregnancies in patients with homozygous antithrombin (AT) deficiency are very rare. We conducted a retrospective, descriptive investigation with emphasis on the obstetric history of eight women with homozygous AT deficiency heparin-binding site (HBS), who had at least one pregnancy. The aim of the study was to get a better insight into the outcome and identify suitable management procedures of pregnancy in this rare disease. All patients suffered from homozygous AT deficiency caused by the mutation c...
March 30, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28343273/pharmacokinetic-comparison-of-cyclosporin-a-and-tacrolimus-in-graft-versus-host-disease-prophylaxis
#19
Ivan Sergeevich Moiseev, Ekaterina Andreevna Burmina, Albert Radikovich Muslimov, Olga Vladislavovna Pirogova, Sergey Nikolaevich Bondarenko, Elena Igorevna Darskaya, Yuliya Alexandrovna Tarakanova, Nadegda Georgievna Senina, Boris Vladimirovich Afanasyev
A number of studies were published with contradictory results comparing tacrolimus (Tac) and cyclosporine A (CsA) for graft-versus-host disease (GVHD) prophylaxis, but there are only few that accounted for pharmacokinetic (PK) parameters. In this study, we created a model based on median concentrations, variability of concentrations, and failures to maintain target levels that distinguished patients with low, intermediate, and high risks of acute GVHD (hazard ratios (HR) 1.77, 95%CI 1.36-2.32, p < 0.0001)...
March 25, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28343272/effect-of-atra-and-ato-on-the-expression-of-tissue-factor-in-nb4-acute-promyelocytic-leukemia-cells-and-regulatory-function-of-the-inflammatory-cytokines-tnf-and-il-1%C3%AE
#20
Sylvie Dunoyer-Geindre, Anne-Sophie Rivier-Cordey, Olga Tsopra, Thomas Lecompte, Egbert K O Kruithof
The characteristic hemorrhages of acute promyelocytic leukemia (APL) are caused in part by the high expression of tissue factor (TF) on leukemic cells, which also produce TNF and IL-1β, proinflammatory cytokines known to increase TF in various cell types. Exposure of NB4 cells, an APL cell line, to all-trans retinoic acid (ATRA) or arsenic trioxide (ATO) rapidly and strongly reduced TF mRNA. Both drugs also reduced TNF mRNA, but later, and moreover increased IL-1β mRNA. The effect on procoagulant activity of cells and microparticles, as measured with calibrated automated thrombography, was delayed and only partial at 24 h...
March 25, 2017: Annals of Hematology
journal
journal
30731
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"